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Rate of Inactivation of Isoniazid in South Indian
Patients with Pulmonary Tuberculosis *  
1. Microbiological Assay of Isoniazid in Serum
following a Standard Intramuscular Dose
P. R. J. GANGADHARAM, A. L. BHATIA, S. RADHAKRISHNA & J. B. SELKON
Since isoniazid is metabolized in man to several derivatives with little or no specific   
activity against the tubercle bacillus, its rate of inactivation in the body may have an impor-
tant bearing on its efficacy as an antituberculosis drug. The inactivation rate, though
constant in any one person, is known to vary from individual to individual and from  
race to race. A series of studies on the rate of inactivation of isoniazid in Indian patients
with pulmonary tuberculosis has recently been undertaken at the Tuberculosis Chemo-
  therapy Centre, Madras. The present paper describes the first of these studies, in which the
concentration of isoniazid in the serum of patients admitted to a controlled comparison of
four domiciliary chemotherapeutic regimens was determined by microbiological assay
four-and-a-half hours after administration of a standard dose of isoniazid (3 mg/kg
body-weight). Patients with serumlevels of 0.58 µg/ml or more were classified
as slow inactivators of isoniazid and those with levels below 0.58 µg/ml as rapid
inactivators. By this definition, 195 (61%) of the 321 patients studied were found to
be slow inactivators and 126 (39%) rapidin ctivators. A relationship was shown
between sex and the rate of inactivation, there being a significantly higher propor-
tion of rapid inactivators among the females than among the males. The observed
  estimates, of the error of the microbiological assay procedure are discussed and possible
ways of reducing the error suggested.
INTRODUCTION 
Isoniazid is metabolized in man to several deriva-
tives of little or no antimicrobial activity against
the tubercle bacillus (Bernstein et al., 1952 ; Hughes,
1953; Cuthbertson, Ireland & Wolff 1953). The
rate of inactivation of isoniazid varies widely from
subject to subject (Hughes, Schmidt & Biehl, 1955;
Middlebrook & Dressler, 1956), but is constant for
a given individual (Hughes, Schmidt & Biehl,
 1955; Bell & Riemensnider, 1957b). The catalase
activity and the degree of isoniazid-resistance of
strains of tubercle bacilli isolated from patients
(Mandel et al., 1957; Canetti & Grosset, 1958);
the isoniazid-resistant strains which emerged during
treatment in slow inactivators had a higher degree of     
resistance and were more frequently catalase-   
negative than the corresponding strains from rapid
inactivators. Mitchell & Bell (1957) have provided  
suggestive evidence that the rate of inactivation of
isoniazid influences the speed with which sputum
conversion occurs.
during treatment with isoniazid have been shown to
be related to the rate of inactivation of isoniazid
* From the Tuberculosis Chemotherapy Centre, Madras,
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the World Health Organization and the Medical Research
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The relationship between the rate of inactivation
of isoniazid and the response to treatment has,
therefore, been investigated in 321 of the 341
patients admitted to a controlled study of four
different chemotherapeutic regimens administered
at home, undertaken by the Tuberculosis Chemo-
therapy Centre (1960). In three of the regimens
isoniazid was the sole antimicrobial agent, and in
the fourth it was given with PAS. The serum iso-
niazid concentrations were determined after a
– 7 6 5  –
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standard test-dose of 3 mg/kg isoniazid. The test-
dose of isoniazid was given by intramuscular injec-
tion instead of by mouth to avoid irregularities in
absorption from the intestinal tract, as the patients,
being treated at home, were not amenable to the
dietary restrictions recommended by Bell & Riemen-
snider (1957b). The serum isoniazid concentrations
were determined by the microbiological assay
method of Mandel et al. (1956) in preference
to chemical methods (Kelly & Poet, 1952;
Cuthbertson et al., 1954; Short, 1954; Poole &
Meyer, 1958; Berte et al., 1959) as the latter are
either too cumbersome, not sufficiently sensitive or
not specific for the antimicrobially active free iso-
niazid and hydrazones.
We report here investigations on the microbiologi-
cal assay technique and the results of determinations
of isoniazid inactivation rates of the patients in the
controlled study. Other articles in this issue are
concerned with the serum isoniazid concentrations
in these patients when they were receiving their
prescribed chemotherapy (Gangadharam et al.,
1961 1) and with the relationship between the rate
of inactivation of isoniazid and the response to
treatment (Selkon et al., 1961 2).
MATERIALS AND METHODS
The 341 patients admitted to the controlled com-
parison of four regimens of domiciliary chemo-
therapy (Tuberculosis Chemotherapy Centre, 1960)
had newly diagnosed pulmonary tuberculosis, and
were aged 12 years or more.
The four prescribed regimens were:
PH. Isoniazid 3.9-5.5 mg/kg body-weight plus
PAS (sodium) 0.2-0.3 g/kg daily, divided into two
doses, by mouth.
HZ-1. Isoniazid alone, 7.8-9.6 mg/kg daily, in one
dose by mouth.
HZ-2. Isoniazid alone, 7.8-9.6 mg/kg daily, divided
into two doses, by mouth.
H. Isoniazid alone, 3.9-5.5 mg/kg daily, divided
into two doses, by mouth.
Of the 341 patients, three are not considered in
this report since they had received more than two
weeks of antituberculosis chemotherapy prior to
admission to the study; the vast majority (96.2%)
of the remaining 338 patients had received none.
1 See article on page 793.
2 See article on page 779.
Th  results of the isoniazid inactivation rates of
17 patients were not available for the following
rea ons: 12 patients had died before the earliest
month selected for the test; two had taken their
discharge against medical advice; in two patients the
t sts were contaminated and in one patient the veni-
puncture was performed after five instead of four-
and- -half hours. The isoniazid inactivation rates of
the remaining 321 patients were determined between
their sixth and twelfth months of treatment. Ad-
ditional investigations (see pages 770 and 771) were
carried out on 16 newly diagnosed patients who
fulfilled the criteria required for admission to the
contr lled study (TuberculosisChemotherapy
Centre, 1960).
Procedure
The patient was taken off all drugs for two days
b fore the test. In order to confirm that the treat-
ment had, in fact, been discontinued, a specimen of
urine was collected immediately before the injection
of isoniazid and examined for the presence of iso-
niazid by the combined naphthoquinone-mercuric
chloride test (Gangadharam et al., 1958). A test-
dose of 3 mg/kg body-weight isoniazid 3 w s given
by intramuscular injection and a specimen of venous
blood was collected four-and-a-half hours later.
No dietary restrictions were imposed on the patient
ither before or during the test.
Culture medium
Liqui  7H-10 medium (Cohn, Middlebrook &
Russell, 1959), without glycerol, was used in this
investigation, with the following modifications:
(a) For growth of the inoculum, the medium
contained; in addition to the basic ingredients, 0.5 %
bovine albumin fraction V (Armour Laboratories),
0.2% glucose, 0.05 % Tween 80 and 50 µg/ml
streptomycin (final concentrations).
(b) For the assay procedure, the medium con-
tained, in addition to the basic ingredients, 0.5%
bovine albumin fraction V, 0.2% glucose, 10 µg/ml
p-aminobenzoic acid and 50 µg/ml streptomycin
(final concentrations).
Assay organism
A culture of Mycobacterium tuberculosis strain
H37RvSR, resistant to streptomycin, obtained by
3 The preparations used were Neoteben (Bayer A.G.,
Leverkusen, Germany) and Isonic (Chemidica S.A., Mon-
treux, Switzerland), supplied in ampoules containing 100
mg/ml isoniazid.
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in vitro selection from strain H37Rv, was used as the
assay organism.It was maintained by monthly
subculture on Löwenstein-Jensen medium contain-
ing 1024 µg/ml streptomycin.
Test
A 1/5 dilution of the serum was prepared by adding
2.0 ml of the serum to 8.0 ml of the 7H-10 test
medium. Serial twofold dilutions, from 1/10 to 1/80,
were then prepared by adding 1.0, 0.5, 0.25 and
0.125 ml of the 1/5 dilution of serum to 7H-10 test
medium, to make up the final volume to 2.0 ml.
Whenever sufficient serum was available (95% of
    sera), tests were set up in duplicate from the same
 1/5 dilution of the serum. The 2.0-ml volumes of the
1/5 to 1/80 dilutions of serum were inoculated with
0.1 ml of an 8-day-old culture of H37RvSR grown in
the Tween-containing 7H-10 liquid medium, and
then incubated at 37°C for five days. Smears were
prepared by pipetting the unshaken deposit of
growth on to slides, with the visual assistance of a
concave mirror. The slides were stained in Coplin
jars by the Ziehl-Neelsen technique and counter-
stained with Loeffler’s methylene blue.
With each batch of tests, a control series of tubes
was set up in duplicate containing 0.00, 0.02, 0.04
and 0.08 µg/ml isoniazid in water, prepared from a
stock solution (100 µg/ml isoniazid) sterilized by
filtration through sintered glass.
Reading and recording of the results
At least six fields of each smear were examined
under x 700 magnification and the proportion of
acid-fast bacilli was estimated as 0 %, 25 %, 50 %,
    75 % or 100 %. The dilution end-point was defined
 as the dilution of serum (the mean dilution if tests
were set up in duplicate) producing 50% loss of
acid-fastness and was determined, where necessary,
by interpolation. For example, if none of the bacilli
in the 1: 10 dilution, and all the bacilli in the 1: 20
dilution were acid-fast, then the dilution which
could have produced 50% loss of acid-fastness was
estimated as 1: 15. The isoniazid concentration of
each test serum was obtained by dividing the geo-
metric mean of the isoniazid concentrations pro-
ducing 50% loss of acid-fastness in the controls set
up in the study by the dilution end-point of the
serum.
RESULTS
The results of the microbiological assays of iso-
niazid were analysed after transformation to a loga-
rithmic scale in which a twofold decrease in the
serum dilution producing 50% loss of acid-fastness,
r  twofold increase in isoniazid concentration,
was given a value of one working unit., One working
unit is, therefore, equivalent to one dilution step in
the assay. In consequence, all mean isoniazid
concentrations quoted are geometric means. Where
appropriate, the transformed values were examined
by analysis of variance.
Investigation of batch differences
The occurrence of variation between different
batches of assays was studied on 399 sera, 321 from
the sa e number of patients (page 766), 30 from
further tests carried out on six of these 321 patients
(page 770) and 48 from the eight additional patients
studied in the investigation reported on page 770. The
isoniazid concentrations of the 399 sera were assayed
in 29 batches of tests, the number of sera tested in
each batch ranging from four to 33. The control
dilutions were contaminated in seven batches,
leaving 22 batches in which the results on the controls
were available. In calculating the isoniazid concen-
tration of a test serum, it is usual (Mandel et al.,
1956) to correct for possible variation from batch to
batch by dividing the concentration of isoniazid
which produces 50% loss of acid-fastness in the
control in the particular batch by the dilution of the
test serum which produces a similar loss of acid-
fastness (the dilution end-point). Such a procedure
assumes that factors affecting the results in any
batch alter the end-point of the test serum and the
control in a similar direction. This assumption was
examined in the following way.
First, the isoniazid concentrations of the test sera
were calculated by employing the controls set up in
in the same batch as the test serum. The averages
of the isoniazid concentrations of the test sera in each
batch are set out under method I in Table 1. The
variation in these averages from batch to batch was
found to be significantly greater than the variation
in isoniazid concentration from serum to serum
within the same batch (P < 0.005). The magnitude
of this batch variation, expressed as a standard
deviation (the square root of the component of
variance due to this source in the analysis of variance),
was 0.32 dilution step.
Secondly, the isoniazid concentrations of the test
sera were calculated by dividing the mean of the
isoniazid concentrations which produced 50% loss
acid-fastness in the controls in the 22 batches
(0.0344 µg/ml isoniazid) by the dilution end-point
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TABLE 1
DISTRIBUTION OF THE MEAN CONCENTRATIONS OF
ISONIAZID IN THE SERA IN DIFFERENT BATCHES OF
TESTS, CALCULATED BY TWO METHODS
Mean concentration
of isoniazid
(µg/ml)
< 0.35
0.35–
0.44–
0.56–
0.70–
0.88–
> 1.11
Total 22 101 29 98
Test batches
Calculated from Calculated from
control in each the mean of
batch controls in
(method I) all batches(method II)
No. % No. %
0 (0)
a 1 3
3 (14) 1 3
6 (27) 14 48
6 (27) 3 10
5 (23) 5 17
1 (5) 5 17
1 (5)  0 0
a The parentheses indicate percentages based on fewer
than 25 observations.
of the serum. The averages of the isoniazid concen-
trations in the 29 batches expressed in this way are
set out under method II in Table 1. Again, the
variation of these averages from batch to batch
was significantly greater than the variation from
serum to serum within the same batch (P = 0.01).
The magnitude of the batch variation, also expressed
as a standard deviation, was 0.26 dilution step, an
estimate lower than the corresponding estimate of
0.32 obtained by the first method. Thus, there is no
evidence from our results that the factors responsible
for batch variation altered the end-points of the
test serum and the control in the same direction in
each batch. In calculating the isoniazid concentra-
tions of the test sera the second method was therefore
employed.
The concentrations of isoniazid which produced
50 % loss of acid-fastness in the controls set up in the
22 batches are presented in Table 2. The distribution
of these concentrations has a mean of 0.0344 µg/ml
and a range of 0.030-0.060 µg/ml. The skewness of
this distribution suggests that a single factor, such
as the ability of the test organisms to grow in the
medium, may have been the principal cause of
variation in the control end-points. It will be
appreciated that the dilutions of the test sera, but
not those of the controls, contained human serum
and that the presence of this human serum might have
promoted the growth of the test organism. Thus,
the failure of the controls to diminish batch variation
might be due to this difference.
Effect of streptomycin
In the early stages of the use of the microbiological
assay procedure in this laboratory, 39 (7.5%) of
522 tests set up were contaminated. Streptomycin
50 µg/ml (final concentration) was therefore added
to both the medium used for growing the test
organism and that used for microbiological assay.  
This alteration in the technique was followed by a
reduction of the contamination rate to 0.5% of the
1005 subsequent tests. In order to be certain, how-
ever, that the addition of streptomycin did not
influence the microbiological assay of isoniazid, the
following investigation was conducted. The iso-
niazid concentrations of seven sera were determined
by three different methods. In method A, a medium
containing 50 µg/ml streptomycin was inoculated
with a culture of H37RvSR grown in a medium
containing the same concentration of streptomycin.
In method B, a medium not containing streptomycin
was inoculated with the culture of H37RvSR grown
in a medium containing 50 µg/ml streptomycin. In
TABLE 2
DISTRIBUTION OF THE CONTROL CONCENTRATIONS
OF ISONIAZID WHICH PRODUCED 50% LOSS
OF ACID-FASTNESS IN DIFFERENT BATCHES OF TESTS
Concentration of isoniazid
which produced 50 % loss
of acid-fastness a
(µg/ml)
Control batches
No. % 
0.030
0.035
0.037
0.040
0.046
0.053
0.060
Total
13 (59) b
2 (9)
2 (9)
2 (9)
1 (5)
1 (5)
1 (5)
22 101
a Mean concentration which produced 50% loss of acid-
fastness = 0.0344 µg/ml.
b The parentheses indicate percentages based on fewer
than 25 observations.
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method C, neither the medium used for the assay nor
that used for growing the inoculum contained strepto-
mycin. The smears prepared from these tests were
examined in a random order. The mean concentra-
tion of isoniazid for the seven sera was estimated as
0.32 µg/ml with method A, 0.46 µg/ml with method
B, and 0.36 µg/ml with method C. As the differences
are neither in the same direction nor statistically
significant, it can be concluded that the addition of
streptomycin did not interfere with the assay of
isoniazid.
Stability of isoniazid in serum during storage in the
deep-freeze
As sera were generally stored in the deep-freeze
at -20°C, sometimes for many weeks, before their
isoniazid concentrations were estimated, the stability
of isoniazid in serum during storage was investigated.
The isoniazid concentrations of 10 sera were assayed
within 12 hours of collection of the blood from the
patients and then again at the end of two, four, six
and eight weeks of storage in the deep-freeze. The
smears prepared from these tests were heat-fixed
and then kept for staining until all the smears were
available. They were stained in one batch and the
slides were read in a random order. The results of
this experiment are presented in Tables 3 and 4.
The concentration of isoniazid decreased from week
to week and there was a linear relationship between
the log concentration and the duration of storage
(Table 4, term c, P < 0.001). The fall in the isoniazid
concentration during storage is estimated as 3.7%
Term
TABLE 3
STABILITY OF ISONIAZID IN SERUM DURING
STORAGE AT -20°C
Serum
number Weeks of storage at -10°C
0 2 4 6 8
1 0.29 0.29 0.29 0.26 0.26
2 1.04 1.04 1.04 0.93 0.69
3 0.29 0.29 0.29 0.26 0.23 a
4 1.04 1.14 1.04 1.04 1.04
5 1.04 1.04 1.04 1.04 0.69
6 1.04 1.14 1.04 0.93 0.69
7 0.26 0.26 0.23 0.17 0.17
6 2.07 1.37 1.14 1.04 1.04
9 1.04 1.04 1.04 0.92 1.04
10 1.04 1.04 1.04 0.69 0.92
Mean (µg/ml) 0.75 0.74 0.70 0.61 0.57
Serum concentration of isoniazid (µg/ml)
Source of variation
Sera
Weeks of storage
Linear regression
Deviation from regression
Residual
Total
a One missing value has been estimated using standard
statistical techniques.
per week. This estimate has been used to correct
the r sults obtained with sera which had been stored
for more than seven days before being assayed. In
contrast to these findings with serum, a solution of
100 µg/ml isoniazid in water, stored at 4°C and
TABLE 4
ANALYSIS OF VARIANCE OF DATA IN TABLE 3
Sum of
squares
43.6575
1.2536
1.1653
0.0883
1.1631
46.0742
I Mean
square
9 4.8508
4 0.3134
1 1.1653
3 0.0294
35 b 0.0332
48 b
F
9.44
35.09
–
a NS indicates that the variance ratio is less than 1.0.
b One missing value has been estimated using standard statistical techniques.
P
<0.001
<0.001
N Sa
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TABLE 5
CONSISTENCY OF INDIVIDUAL ISONIAZID INACTIVATION RATES
Treatment Number
regimen of patients
PH
HI-1
HI-2
H
All regimens
Before
treatment
0.58
0.31
0.84
0.26
Duration of treatment
7 days 3 month 6 months 9 months  12 months
I
0.53 0.56 0.62 0.65 0.54
0.36 0.25 0.43 0.41 0.29
0.84 0.84 1.04 1.09 1.14
0.31 0.43 0.42 0.50 0.44
0.47 0.57 0.60 0.54             
Mean serum concentration of isoniazid (µg/ml)
tested concurrently with the sera, showed no altera-
tion in the concentration of isoniazid during six
weeks of storage.
Consistency of individual isoniazid inactivation rates
The consistency of individual rates of inactivation
of isoniazid was investigated in 14 patients (6 PH,
3 HI-1, 2 HI-2, 3H), six of whom were part of the
main population of 321 patients under study (page
766). Serum concentrations of isoniazid were deter-
mined four-and-a-half hours after an intramuscular
test-dose of 3 mg/kg isoniazid, just before treatment
was started, and then again after seven days and
after three, six, nine and 12 months of treatment.
The results are set out in Table 5. Considering all
treatment groups, there was a very slight suggestion
of an increase in the mean concentration of isoniazid
with time. The trend (linear regression), however,
is not statistically significant (0.1 < P < 0.2). This
applied to all four regimens.
The mean weight of the 14 patients was 82.6 lb.
(range, 59-109 lb.) on admission to treatment,
88.4 lb. at six months and 89.8 lb. at 12 months.
Accuracy of the test
The error of the test procedure for determining
the isoniazid inactivation rate on different occasions
in a patient is composed of the error of the micro-
biological assay and of other procedures in the test,
such as inadvertent variation in the test-dose of
isoniazid injected and variation in its rate of absorp-
tion. During the course of the study, a number of
estimates were made of the variation from different
sources that contributed to the error of the test
procedure. These are set out in Table 6.
Error of the assay procedure.Estimates of the varia-
tion from assay to assay, carried out on the same
test serum in the same batch of assays, were obtained
from (a) the experiment on the stability of isoniazid
in serum during storage in the deep-freeze (Table 6,
term a), and (b) the untabulated results of duplicate
tests on 65 sera, which were set up and read in a
random order (Table 6, term b). Combining these
estimates, the standard deviation was 0.15 dilution
step (Table 6, term c).Since this variation was
between assays in the same batch, and since differ-
nces from batch to batch were found to be signifi-
cant (page 767), an estimate of the total error of the
assay is provided by adding to the former, the
variation from batch to batch (Table 6, term d,
0.26 dilution step). Thus calculated, the total error
was 0.30 dilution step when expressed as a standard
deviation (Table 6, term e). As an example of the
interpretation of this estimate in terms of isoniazid
concentrations, if 20 assays, randomly distributed
in different batches, were carried out on the same
serum with an isoniazid concentration of 1.0 µg/ml,
then in 19 of these assays the estimated concentra-
tion would be expected to be between 1.50 and 0.67
µg/ml.
Err r of the test procedure.The error of the test
procedure–that is, the variation in the determina-
ions of the serum isoniazid concentration on differ-
ent occasions on the same patient–was estimated
from (a) the results of multiple tests on the same
patient in the experiment on the consistency of indi-
v dual isoniazid inactivation rates (Table 6, term f),
and (b) the results of duplicate tests (not tabulated
here) carried out on 43 patients, at six and 12 months
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TABLE 6
ESTIMATES OF ERROR DUE TO DIFFERENT SOURCES IN THE DETERMINATION OF SERUM CONCENTRATION
OF ISONIAZID IN PATIENTS FOUR-AND-A-HALF HOURS AFTER AN INTRAMUSCULAR TEST-DOSE
OF 3 mg/kg ISONIAZID
Source of error
Assay procedure:
Between assays on same serum in same batch
Between batches of tests
Between assays on same serum
Test procedure :
Between tests on same patient
Test procedures other than in the assay h-e
Term Source of estimate
Table 4, term e a
Page 770 b
Combined estimate (a and b)
Page 770 ; Table 1c
c + d
Estimate of error
35
65
100
28
Table 5 d 67
Page 770 e 42
Combined estimate (f and g) 109
a Residual from experiment on the effect of storage of sera at –10°C.
b Between duplicate tests on the same serum.
c Between batches of tests.
d Between tests on the same patient from experiment on the stability of individual isoniazid inactivation rates.
0.18
0.14
0.15
0.26
0.30
0.60
0.44
0.54
0.45
e Between patients with test results at six and 12 months.
(Table 6, term g). The combined estimate (Table 6,
term h) of this variation, expressed as a standard
deviation, was 0.54 dilution step. If 20 test procedures
were carried out on different occasions on the same
patient, and the mean of the serum isoniazid con-
centrations at four-and-a-half hours was 1.0 µg/ml,
then in 19 of these tests the isoniazid concentration
would be expected to be between 2.08 and 0.48 µg/ml.
Error of the test procedures apart from the assay.
The error of the test procedures apart from the assay
was calculated by subtracting the error of the micro-
biological assay from the total error of the test proce-
dures. Expressed as a standard deviation, this error
was equal to 0.45 dilution step (Table 6, term i).
Serial serum concentrations from half an hour to
five-and-a-half hours
Serial isoniazid serum concentrations were deter-
mined in eight newly diagnosed, previously un-
treated patients half an hour, one hour, and two,
four-and-a-half and five-and-a-half hours after an
intramuscular injection of 3 mg/kg isoniazid. The
results are presented in Table 7 and in Fig. 1. At
four-and-a-half hours, five of the eight patients had
s rum concentrations above 0.58 µg/ml and three
had serum concentrations below 0.58 µg/ml. For
reasons given in the next section, the former have
been classified as slow inactivators and the latter
as rapid inactivators of isoniazid.
The highest mean serum concentration observed
for the five slow inactivators was 2.60 µg/ml and
that for the three rapid inactivators was 2.18 µg/ml.
The serum concentrations at half an hour varied
considerably between patients and there was no
clear difference between rapid and slow inactivators.
At one hour, a difference was discernible, but there
was still considerable variation between patients in
the same inactivation group and slight overlapping
between the groups. The variation between patients
in th  same inactivation group was markedly less
at two, four-and-a-half and five-and-a-half hours
and there was a clear distinction between the mean
conce trations of the slow and rapid inactivators.
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TABLE 7
SERUM CONCENTRATIONS OF ISONIAZID AT DIFFERENT
INTERVALS AFTER INTRAMUSCULAR INJECTION
OF 3 mg/kg ISONIAZID
 Serum concentration of isoniazid
(µg/ml)
Hours after administration
of test dose
1 1.82 2.75 2.06 1.03 1.03
2 3.68 2.75 2.06 1.17 1.03
3 2.06 2.06 2.06 1.03 1.03
Slow 4 2.75 2.75 1.82 1.38 1.17
5 2.30 2.75 2.06 1.11 1.03
 Mean   2.44  2.60  2.01  1.15  1.06
1 3.68 2.06 1.03 0.34 –
2 2.75 1.38 1.38 0.34 0.17
Rapid 3 1.03 2.06 1.03 0.52 0.34
 Mean  2.18  1.80  1.14  0.39  0.24
The mean concentration of the slow inactivators was
1.8 times that of the rapid inactivators at two hours,
2.9 times at four-and-a-half hours and 4.4 times at
five-and-a-half hours.
Distribution of serum concentrations of isoniazid of
South Indian patients
The distribution of the serum concentrations of
isoniazid of the 321 South Indian patients (page 766)
four-and-a-half hours after an intramuscular injec-
tion of 3 mg/kg of isoniazid is set out in Fig. 2. The
distribution is bimodal and appears to consist of
two normal distributions which overlap, particul-
arly in the 0.49-0.69 µg/ml class interval. The means
of the two distributions are approximately 0.30
and 1.10 µg/ml. In order to determine whether the
38 patients in the 0.49-0.69 µg/ml class interval
really did belong to one or other of these distribu-
tions and were not a group with an intermediate
rate of inactivation, the rate of inactivation of iso-
niazid of 37 of them was retested.Of the 37 patients
who were retested, 17 (46%) had serum concentra-
tions above 0.69 µg/rnl and 9 (24 %) below 0.49 µg/ml.
Although this evidence does not exclude the possibi-
FIG. 1
SERIAL MEAN SERUM CONCENTRATIONS OF ISONIAZID
(INH) IN FIVE SLOW AND THREE RAPID INACTIVATORS
AFTER AN INTRAMUSCULAR DOSE OF 3 mg/kg
BODY-WEIGHT
6.4
0.1 .
0 1 2 3 4 5 6
HOURS AFTER INJECTION
The dotted and solid vertical lines indicate the range of the
observations for the slow and rapid inactivators, respectively.
lity of there being an intermediate group, it does
suggest that at least the majority of patients in this
class interval do belong to one or other of the main
distributions. It was therefore decided to separate
the two distributions arbitrarily at the mid-point
(0.58 µg/ml) of this class interval and to classify
thos  with serum concentrations at or above 0.58
µg/ml as slow inactivators of isoniazid and those
with serum concentrations below 0.58 µg/ml as
rapid inactivators. According to this classification,
195 (61%) of the 321 patients were slow inactivators
and 126 (39%) were rapid inactivators.
The standard deviation of the serum concentra-
tions of isoniazid for the slow inactivators was
e imated to be 0.54 dilution step. It was shown on
page 771 that the error of the test procedure was also
estimated as 0.54 dilution step. Thus, all of the
variation among the slow inactivators is likely to be
du  o the error of the test procedure. The corres-
ponding standard deviation for the rapid inactivators
could not be estimated as a relatively large proportion
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FIG. 2
DISTRIBUTION OF SERUM CONCENTRATIONS
OF ISONIAZID (INH) FOUR-AND-A-HALF HOURS AFTER
AN INTRAMUSCULAR DOSE OF 3 mg/kg BODY-WEIGHT
TABLE 8
DISTRIBUTION OF WEIGHTS ACCORDING TO RATE
OF INACTIVATION OF ISONIAZID AND SEX OF PATIENTS
Males
60-69
70-79
80-89
90-99
100-109
110-119
120 or above
Slow
inactivator
No. %
2 1
4 3
26 1 8
56 4 0
26 78
18 1 3
9 6
98.3
Rapid Slow Rapid
nactivators inactivators inactivators
No. % No. % No. %
1 1
4 6
9 13
21 3 0
20 2 8
8 11
8 11
71 1 00
4 7 10 1 8
14 2 6 16 2 9
17 3 1 16 2 9
13 2 4 7 13
3 6 6 11
3 6 0 0
0 0 0 0
54 1 00 55 1 00
100.4 85.9 81.2
s    i
0.17 0.24 0.34 0.49 0.69 0.97 1.37 1.93 2.73
Total
Mean
CONCENTRATION OF INH (µg/ml)
The number above each block indicates the number of
patients on whom determinations of serum concentrations of
isoniazid were made.
a 1 lb.= 0.45 kg.
females, the difference being highly significant
(P < 0.01). A sub-analysis was undertaken to see if
this difference was evident in the various weight-
groups and the findings are presented in Table 9.
It can be seen that the proportion of slow inactivators
among the males is uniformly higher in all the weight-
groups than the corresponding proportion for the
of the patients had serum concentrations of isoniazid
below the level of sensitivity of the assay.
Relationship between sex, body-weight, age and rate
of inactivation of isoniazid
There was no evidence. of an association between
the serum concentration of isoniazid and body-
weight either among the 195 slow inactivators
(correlation coefficient (r) = 0.11, P = 0.1-0.2)
or among the 126 rapid inactivators (r = 0.17,
P= 0.07). The distribution of weights for the slow
and rapid inactivators is presented, separately for
males and females, in Table 8. Considering the
males, the weight distributions for the slow and rapid
inactivators are very similar, the means being 98.3
and 100.4 lb., respectively. Among females, there
was a slight suggestion that the rapid inactivators
weighed less than the slow inactivators; thus, 10
(18% of the 55 rapid inactivators weighed 60-69 lb.
as compared with four (7%) of the 54 slow inactiva-
tors (P ~ 0.2). The mean weight for the rapid
inactivators was 81.2 lb. as compared with 85.9 lb.
for the slow inactivators (P ~ 0.06).
Of 212 male patients, 141 (67%) were slow
inactivators as compared with 54 (50%) of 109
TABLE 9
PROPORTION OF SLOW INACTIVATORS AMONG MALE
AND FEMALE PATIENTS ACCORDING TO BODY-WEIGHT
Males I Females
Total
60-79 11 (55)* 44 41
80-89 35 74 33 52
90-99 77 73 20 (65)
100 or above 89 60 12 (50)
Total 212 67 50
a I lb. = 0.45 kg.
b The parentheses indicate percentages based on fewer
than 25 observations.
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females. It may therefore be concluded that the
difference between the sexes in respect of the rate of
inactivation of isoniazid cannot be attributed to
differences in body-weight and is presumably a
genuine sex difference. An analysis (not tabulated
here) revealed that there was no association between
the rate of inactivation of isoniazid and the age of
the patient.
DISCUSSION
The results of determinations of the rate of inacti-
vation of isoniazid reported here have demonstrated
that South Indian patients can be divided into two
groups–namely, the rapid and the slow inactivators
– as has been previously reported for North Ameri-
can patients (Middlebrook & Dressler, 1956; Price
Evans, 1959). The success of a method for determin-
ing the rate of inactivation of isoniazid can best be
judged by its ability to distinguish these two groups of
patients. In this study, 38 (12%) of the 321 patients
had serum concentrations between 0.49 and 0.69
µg/ml, the class interval in which the distributions of
the slow and rapid inactivators overlapped, and thus
could not be assigned with certainty to either of these
two groups.This percentage of indeterminate
results may be compared broadly with the estimates
of other workers (Mandel et al., 1959; Price Evans,
1959), although there were differences between the
three studies, not only in the procedures employed,
but also in the class intervals used for grouping the
isoniazid assay results. The results of the above-
mentioned workers are rather more satisfactory than
those reported here; thus, 1.5 % of the 254 patients
studied by Mandel et al. (1959) and 8 % of the
123 patients reported by Price Evans (1959) had
indeterminate serum concentrations of isoniazid.
It is therefore necessary to consider modifications of
the technique used at the Tuberculosis Chemo-
therapy Centre which could eliminate or decrease the
proportion of patients with indeterminate results.
Increased precision in classifying patients as rapid
or slow inactivators can be obtained in two ways:
(a) by increasing the difference between the means of
the distributions for the slow and rapid inactivators,
and (b) by decreasing the variation within each of
these distributions. Considering the first approach,
the results of serial assays on patients indicate that
the longer the period between the peak serum con-
centration and the collection of blood for assay, the
greater is the difference in the mean serum concen-
trations of isoniazid between the rapid and the slow
inactivators. Middlebrook & Dressler (1956) recom-
mend d six hours as the optimum period after
oral administration of a 4 mg/kg test-dose. In this
study, an interval of four-and-a-half hours between
the administration of the test-dose and the collection
of blood was chosen, because it was thought that the
difference between the times when peak serum
concentrations are attained following intramuscular
and oral administration would be about one-and-a-
half hours. Peak serum isoniazid concentrations
were, however, achieved after about 30 minutes
following the intramuscular injection of the test-
dose, and after about 70 minutes following oral
administration of a dose of about the same size   
(Gangadharam et al., 1961 1), a difference of only
40 minutes. The original estimate of one-and-a-half
hours was thus 50 minutes too long.However, if the
period between administering the test-dose and
collecting the blood had been prolonged beyond
f r-and-a-half hours, a larger proportion of sera
would have contained concentrations of isoniazid
that were below the limit of sensitivity of the assay
method, and this would have impaired the statistical
alysi  of the results. A longer interval than
f ur-and-a-half hours could, however, be employed
if a larger test-dose of isoniazid than 3 mg/kg were
used. In future studies at the Tuberculosis Chemo-
therapy Centre it is proposed to administer an intra-
muscular test-dose of 6 mg/kg isoniazid and to collect
blo d six hours later.
Considering the second approach, a decrease in
the ariation from patient to patient within each of
the two inactivation groups would also result in
greater precision in the classification of the patients.
Owing to the presence of the patients who could not      
be cl ssified as slow or rapid inactivators with cer-
tainty, and because a proportion of assay results
lay below or above the range of the method, exact
esti ates of the standard deviations of the distribu-
tions of rapid and slow inactivators could not be
calculated. Nevertheless, it appears probable that
the error of the test procedure-that is, the varia-
tion from test to test on the same patient-accounted
for the variation from patient to patient in the
group of slow inactivators, which is the better defined
of the two distributions (Fig. 2).
In considering the error of the test procedure, it is
important to realize that it is derived from two
sources.The source yielding the greater part of the
error (standard deviation of 0.45 dilution step) con-
1 See article on page 793.
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sists of the effects of factors other than the micro-
biological assay, such as possible inaccuracies in the
measurement of the test-dose or variations in its
rate of absorption.These two sources of error might
be controlled by injecting a carefully measured dose in
a large volume by the intravenous route. Jenne (1960),
however, using the intravenous route, obtained a
similar proportion of indeterminate results to that
encountered in our study. The second source is the
error of the assay itself, which has a slightly smaller
standard deviation (0.30 dilution step). A consider-
able portion of this error was due to batch variation,
and it is a disturbing comment on the present method
    that the controls set up to eliminate this variation
entirely failed to do so. While it has not been possible
to define and estimate all the causes of error in the
test procedure, it is believed that the estimates
obtained of certain variations which contributed to
it have been helpful in indicating which aspects of
the test should receive most attention in future
attempts to reduce the error. In the meantime, until
a procedure is available which completely separates
the distributions of slow and rapid inactivators,
it would seem advisable to carry out repeat tests on
those patients whose first results are indeterminate,
and classify them on the basis of the mean of the
two tests.
Mandel et al. (1956) had previously reported that
the microbiological assay of isoniazid was un-
affected by the addition of 100 µg/ml streptomycin
to undiluted human serum. However, these authors
did not report the concentration of streptomycin
present in the serum dilution which produced 50%
loss of acid-fastness. The present investigation has
shown that 50 µg/ml streptomycin added to the assay
medium probably did not interfere with the assay,
and was responsible for a marked reduction in con-
tamination rates.
The finding in the present study that isoniazid
in serum was destroyed at a rate of 3.7% per week
for eight weeks during storage at –20°C is at
variance with the findings of Bell & Riemensnider
(1957a), who reported that there was no loss of iso-
niazid on up to 21 weeks’ storage in the deep-freeze.
The rate of inactivation of isoniazid has been
shown to be determined genetically, slow inactiva-
tion being a simple Mendelian recessive trait (Knight,
Selin & Harris, 1959; Price Evans, 1959) which occurs
with different frequencies in different racial groups
(Harris, Knight & Selin, 1958; Armstrong & Peart,
1959). Harris, Knight & Selin (1958) found that
44% of Americans of Caucasian ancestry were slow
inactivators, as compared with 12% of Americans
of Japanese descent, and Armstrong & Peart (1959)
fou d hat only 5% of Eskimos were slow inactiva-
tors as compared with 56% of non-Eskimos. Price
Evans (1959) found that 52 % of Americans of
Caucasian ancestry were slow inactivators and the
remainder rapid inactivators. Our finding that the
proportion of slow inactivators in Indian patients
wa  61% is thus similar to the proportion of this
group in Americans of Caucasian descent.
The relationship shown in this study between the
rate f inactivation of isoniazid and sex is different
from the findings of Price Evans (1959). In our
investigation, the proportion of rapid inactivators
among female patients was significantly higher than
that among male patients and this difference could
not be accounted for by differences in body-weight.
Price Evans (1959), on the other hand, demonstrated
a relationship between the rate of inactivation of
isoniazid and body-weight, but not between the rate
of inactivation and sex. It is difficult to explain this
discrepancy. It may be due to the fact that his popu-
lati n contained a larger proportion of children.
We have no definite information on the effect of
mal u rition on the rate of inactivation of isoniazid.
Suggestive evidence is, however, afforded by the
serial determinations of the inactivation rates of
14 patients that were done on admission to treatment
and after three, six, nine and 12 months of treatment.
Although the patients were malnourished on ad-
missi n to treatment and gained, on the average,
7 lb. i  weight during the 12 months of treatment,
there was no corresponding alteration in their rates
of inactivation of isoniazid.
SUMMARY
1. The serum isoniazid concentrations were
determined four-and-a-half hours after an intra-
muscular injection of 3 mg/kg isoniazid in 321 of
341 patients participating in a controlled chemo-
therapy study.
2. The addition of streptomycin in a final concen-
tration of 50 µg/ml was found to have no effect on
the assay.
3. Isoniazid in serum was destroyed at a rate of
3.7% per week for eight weeks during storage at
– 20°C.
4. Estimates were obtained of the error of the
procedure for determining the rate of inactivation
of is niazid (0.54 dilution step) and for the method
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of microbiological assay of isoniazid in serum (0.30 and those with less than 0.58 µg/ml as rapid inacti-
dilution step). The error due to factors other thanva ors. Of the 321 patients studied, 195 (61%) were
that of the microbiological assay method was esti-clas if ed as slow inactivators and 126 (39 %) as rapid
mated as 0.45 dilution step. inactivators.
5. A defect of the microbiological assay method7. The rate of inactivation of isoniazid in
was the presence of batch variation, which was notindividual patients was found to remain constant
corrected for by the use of isoniazid controls. Theduring 12 months of treatment.
error introduced by batch variation was estimated as
0.26 dilution step.
8. A relationship was shown between sex and the
rate of inactivation of isoniazid, there being a signi-
6. Patients with serum isoniazid concentrations officantly higher proportion of rapid inactivators
0.58 µg/ml or more were classified as slow inactivatorsamong the females as compared with the males.
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